bf/NASDAQ:CYT_icon.jpeg

NASDAQ:CYT

Cyteir Therapeutics, Inc.

  • Stock

USD

Last Close

3.09

15/03 20:00

Market Cap

108.71M

Beta: -

Volume Today

1.01M

Avg: 56.88K

PE Ratio

−3.67

PFCF: −4.34

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '19
Dec '20
Dec '21
Dec '22
revenue
8K
-
cost of revenue
12.69K
-
351K
2,666.18%
479K
36.47%
1.38M
187.06%
gross profit
-4.69K
-
-351K
7,385.60%
-479K
36.47%
-1.38M
187.06%
selling and marketing expenses
general and administrative expenses
3.35M
-
4.18M
24.90%
11.30M
170.46%
13.55M
19.88%
selling general and administrative expenses
3.35M
-
4.18M
24.90%
11.30M
170.46%
13.55M
19.88%
research and development expenses
12.77M
-
16.77M
31.30%
30.96M
84.66%
34.62M
11.84%
other expenses
-8K
-
120K
1,600%
133K
10.83%
2.11M
1,485.71%
cost and expenses
16.11M
-
20.94M
30.04%
42.26M
101.78%
48.17M
13.99%
operating expenses
16.11M
-
20.94M
30.04%
42.26M
101.78%
48.17M
13.99%
interest expense
-668K
-
ebitda
-15.89M
-
-20.59M
29.59%
-42.26M
105.22%
-48.17M
13.99%
operating income
-16.11M
-
-20.94M
30.04%
-42.26M
101.78%
-48.17M
13.99%
depreciation and amortization
215K
-
351K
63.26%
479K
36.47%
668K
39.46%
total other income expenses net
1.06M
-
120K
88.69%
133K
10.83%
2.11M
1,485.71%
income before tax
-15.04M
-
-20.82M
38.41%
-42.13M
102.31%
-46.06M
9.34%
income tax expense
-479K
-
-2.11M
340.29%
net income
-15.04M
-
-20.82M
38.41%
-41.65M
100.00%
-43.95M
5.53%
weighted average shs out
19.43M
-
23.89M
22.93%
19.50M
18.38%
35.27M
80.89%
weighted average shs out dil
19.43M
-
23.89M
22.93%
19.50M
18.38%
35.27M
80.89%
eps
-0.77
-
-0.87
12.99%
-2.14
145.98%
-1.25
41.59%
epsdiluted
-0.77
-
-0.87
12.99%
-2.14
145.98%
-1.25
41.59%

All numbers in USD (except ratios and percentages)